

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7760351

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ANTARES PHARMA IPL AG	01/09/2023
RECEIVING PARTY DATA		
Name:	THE POPULATION COUNCIL, INC.	
Street Address:	ONE DAG HAMMARSKJOLD PLAZA	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10017	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	9682087
CORRESPONDENCE DATA		
Fax Number:	(908)654-7866	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(908) 654-5000	
Email:	assignment@lernerdavid.com	
Correspondent Name:	LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP	
Address Line 1:	20 COMMERCE DR.	
Address Line 4:	CRANFORD, NEW JERSEY 07016	
ATTORNEY DOCKET NUMBER:	CBR 3.3-057	
NAME OF SUBMITTER:	LIZ SEMON	
SIGNATURE:	/Liz Semon/	
DATE SIGNED:	01/25/2023	
Total Attachments: 5		
source=Deed of Assignment CBR 3#page1.tif		
source=Deed of Assignment CBR 3#page2.tif		
source=Deed of Assignment CBR 3#page3.tif		
source=Deed of Assignment CBR 3#page4.tif		
source=Deed of Assignment CBR 3#page5.tif		

DEED OF ASSIGNMENT

THIS DEED OF ASSIGNMENT ("**Assignment**") IS MADE BY AND BETWEEN

Antares Pharma IPL AG (hereinafter "**ASSIGNOR**"), a corporation organized under the laws of Switzerland with its principal place of business located at Baarerstrasse 95, CH-6301 Zug, Switzerland; and

The Population Council, Inc. (hereinafter "**ASSIGNEE**"), a corporation organized under the laws of New York with its principal place of business located at One Dag Hammarskjold Plaza, New York, New York 10017, United States.

WHEREAS:

- A **ASSIGNOR** and **ASSIGNEE** (together, the "**PARTIES**") are parties to that certain Joint Development Agreement, dated as of July 20, 2006 (the "**JDA**"), which has since been terminated by mutual consent of the **PARTIES** (the "**TERMINATION**");
- B **ASSIGNOR** and **ASSIGNEE**, pursuant to the terms of the **JDA**, collectively own the entire right, title and interest in the patents listed in the attached Exhibit A (hereinafter "the **PATENTS**"); and
- C **ASSIGNEE**, as agreed upon in connection with the **TERMINATION**, is acquiring all of the worldwide right, title and interest in and to the **PATENTS** and the inventions disclosed therein.

NOW, THEREFORE, for good and valuable consideration receipt of which is hereby acknowledged, **ASSIGNOR** has sold, assigned and transferred, and does hereby sell, assign and transfer to **ASSIGNEE** all of its entire worldwide right, title and interest in (i) the **PATENTS** and the inventions and improvements disclosed therein; (ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals, reexaminations and foreign counterparts thereof, and other patents, patent applications, certificates of invention other governmental grants resulting from the **PATENTS**; (iii) all patents and applications which claim priority to or have common priority with any such patents or patent applications; and (iv) all rights corresponding to any of the foregoing throughout the world including all rights under any International Conventions for the Protection of Industrial Property, including the Paris Convention and the European Patent Convention and the corresponding rights to claim benefit from the priority of any of the patents or patent applications and the right to sue for and recover damages for any past, present or future infringement of the Patents, the same to be held and enjoyed by **ASSIGNEE** for its own use and enjoyment, and for the use and enjoyment of its successors, assigns and other legal representatives, to the end of the term or terms of said **PATENTS** granted or reissued or reexamined as fully and entirely as the same would have been held and enjoyed by **ASSIGNOR**, if this assignment and sale had not been made.


IN WITNESS WHEREOF, **ASSIGNOR** has caused these presents to be signed by its duly appointed trustee having full authority to convey its property; and **ASSIGNEE** has caused these presents to be signed by its duly appointed trustee.

ASSIGNOR hereby declares that **ASSIGNEE** may take the steps to record this assignment in the sole name of **ASSIGNEE**.

ASSIGNOR hereby undertakes that it shall, without further consideration, but at the expense of **ASSIGNEE**, execute all documents and do such acts as may be reasonably necessary to enable Letters Patent or any other form of protection to be issued in respect of any of said **PATENTS** and the inventions disclosed therein in any part of the world and to enable or to assist **ASSIGNEE** to defend oppositions thereto, to maintain the **PATENTS** and to prosecute for the infringement thereof.

IN WITNESS WHEREOF, the parties by their duly authorized representatives have executed and delivered this Agreement as of the Effective Date.

ANTARES PHARMA IPL AG (ASSIGNOR)


Name: MARK SUMMER
Title: General Counsel

12/12/2022 San Diego CA
Date and Place of Execution

STATE OF _____)

: SS.

COUNTY OF _____)


The person whose name is subscribed to the accompanying instrument is personally known to me or has proved his/her identity to me on the basis of satisfactory evidence. On _____, he/she appeared before me and acknowledged that he/she has read the accompanying instrument and knows the contents thereof, and that he/she executed the same as their free act and deed for the purposes set forth therein. If he/she is acting on behalf of an entity, he/she also acknowledged that he/she executed the accompanying instrument in his/her authorized capacity, and that by his/her signature on the instrument, the entity executed the same.

NOTARY PUBLIC

Residing at _____

My Commission Expires: _____

THE POPULATION COUNCIL, INC. (ASSIGNEE)


Name: James Scitlog
Title: Vice President

1/9/23 New York, NY

Date and Place of Execution

STATE OF New York)

: SS.

COUNTY OF New York)

The person whose name is subscribed to the accompanying instrument is personally known to me or has proved his/her identity to me on the basis of satisfactory evidence. On Jan 9, 2023, he/she appeared before me and acknowledged that he/she has read the accompanying instrument and knows the contents thereof, and that he/she executed the same as their free act and deed for the purposes set forth therein. If he/she is acting on behalf of an entity, he/she also acknowledged that he/she executed the accompanying instrument in his/her authorized capacity, and that by his/her signature on the instrument, the entity executed the same.


KEALA CHAN

Notary Public, State of New York

Reg. No. 02CH6296150

Qualified in Queens County

Commission Expires Apr 13, 2026


NOTARY PUBLIC

Residing at Queens County, New York

See attached
Acknowledgement

EXHIBIT A

ASSIGNED PATENTS AND PATENT APPLICATIONS

Date Format (MM/DD/YYYY)

1. United States Listed Issued Patents and Pending Patent Applications

US Issued Patents

Patent Number	Filing Date	Application Number	Issue Date	Title
9,682,087	Oct. 26, 2012	13/515,552	Jun. 20, 2017	Nestorone®/estradiol Transdermal Gel

2. Foreign Listed Issued Patents and Pending Patent Applications

Foreign Issued Patents

Patent Number	Country	Filing Date	Application Number	Issue Date	Title
2010339867	Australia	Jun. 26, 2012	2010339867	Nov. 6, 2014	Nestorone®/estradiol Transdermal Gel
BR112012014059-0	Brazil	Jun. 8, 2012	BR112012014059-0	March 10, 2020	Nestorone®/estradiol Transdermal Gel
2,782,075	Canada	May 25, 2012	2,782,075	Jun. 30, 2015	Nestorone®/estradiol Transdermal Gel
EP2,512,486	Europe	Jun. 14, 2012	EP10799204.2	Jun. 28, 2017	Nestorone®/estradiol Transdermal Gel
EP2,512,486	France	Jun. 14, 2012	EP10799204.2	Jun. 28, 2017	Nestorone®/estradiol Transdermal Gel
EP2,512,486	Germany	Jun. 14, 2012	EP10799204.2	Jun. 28, 2017	Nestorone®/estradiol Transdermal Gel
EP2,512,486	Italy	Jun. 14, 2012	EP10799204.2	Jun. 28, 2017	Nestorone®/estradiol Transdermal Gel
EP2,512,486	Netherlands	Jun. 14, 2012	EP10799204.2	Jun. 28, 2017	Nestorone®/estradiol Transdermal Gel
EP2,512,486	United Kingdom	Jun. 14, 2012	EP10799204.2	Jun. 28, 2017	Nestorone®/estradiol Transdermal Gel
EP2,512,486	Spain	Jun. 14, 2012	EP10799204.2	Jun. 28, 2017	Nestorone®/estradiol Transdermal Gel
EP2,512,486	Sweden	Jun. 14, 2012	EP10799204.2	Jun. 28, 2017	Nestorone®/estradiol Transdermal Gel
6,082,249	Japan	Jun. 14, 2012	2012-544866	Jan. 27, 2017	Nestorone®/estradiol Transdermal Gel
363536	Mexico	Jun. 12, 2012	MX/a/2012/006755	March 27, 2019	Nestorone®/estradiol Transdermal Gel
600907	New Zealand	Jun. 26, 2012	600907	March 4, 2014	Nestorone®/estradiol Transdermal Gel
2012/04267	South Africa	Jun. 11, 2012	2012/04267	Feb. 27, 2013	Nestorone®/estradiol Transdermal Gel
10-1928321	Republic of Korea	July 12, 2018	10-2018-7019976	Dec. 6, 2018	Progestin/Estradiol Transdermal Gel

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.


State of California
County of San Diego

On December 13, 2022 before me, Patricia Weigand, Notary Public
(insert name and title of the officer)

personally appeared Mark Snyder
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Signature Patricia Weigand (Seal)